SI2176252T1 - 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema - Google Patents

2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema

Info

Publication number: SI2176252T1
Authority: SI; Slovenia
Prior art keywords: 4ćdioxin; peripheric; systeme; diseases; treatment
Prior art date: 2007-07-20

Application number

SI200831313T

Other languages

English (en)

Inventor

Belle David Din

Patrik Holm

Arto Karljalainen

Arto Tolvanen

Gerd Wohlfahrt

Petteri. Rummakko

Original Assignee

Orion Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-20

Filing date

2008-07-18

Publication date

2014-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2176252(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-18 Application filed by Orion Corporation filed Critical Orion Corporation

2014-12-31 Publication of SI2176252T1 publication Critical patent/SI2176252T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SI200831313T 2007-07-20 2008-07-18 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema SI2176252T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US95098307P	2007-07-20	2007-07-20
PCT/FI2008/000090 WO2009013390A1 (en)	2007-07-20	2008-07-18	2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
EP08787689.2A EP2176252B1 (en)	2007-07-20	2008-07-18	2, 3-dihydrobenzo[1, 4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases

Publications (1)

Publication Number	Publication Date
SI2176252T1 true SI2176252T1 (sl)	2014-12-31

Family

ID=39884455

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200831313T SI2176252T1 (sl)	2007-07-20	2008-07-18	2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema

Country Status (32)

Country	Link
US (3)	US8492549B2 (sl)
EP (1)	EP2176252B1 (sl)
JP (1)	JP5460590B2 (sl)
KR (1)	KR101535059B1 (sl)
CN (1)	CN101842369B (sl)
AR (1)	AR069271A1 (sl)
AU (1)	AU2008278924B2 (sl)
BR (1)	BRPI0814529B8 (sl)
CA (1)	CA2693804C (sl)
CL (1)	CL2008002114A1 (sl)
CO (1)	CO6331473A2 (sl)
CY (1)	CY1115789T1 (sl)
DK (1)	DK2176252T3 (sl)
EA (1)	EA017554B1 (sl)
ES (1)	ES2502215T3 (sl)
GE (1)	GEP20125538B (sl)
HK (1)	HK1148530A1 (sl)
HR (1)	HRP20141156T1 (sl)
IL (1)	IL202964A (sl)
MA (1)	MA31521B1 (sl)
MY (1)	MY153872A (sl)
NZ (1)	NZ582432A (sl)
PE (1)	PE20090890A1 (sl)
PL (1)	PL2176252T3 (sl)
PT (1)	PT2176252E (sl)
RS (1)	RS53571B1 (sl)
SI (1)	SI2176252T1 (sl)
TN (1)	TN2010000029A1 (sl)
TW (1)	TWI457122B (sl)
UA (1)	UA100695C2 (sl)
WO (1)	WO2009013390A1 (sl)
ZA (1)	ZA201000314B (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI457122B (zh)	2007-07-20	2014-10-21	Orion Corp	作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
MX2010011498A (es) *	2008-04-29	2010-11-12	Nsab Af Neurosearch Sweden Ab	Moduladores de neurotransmision de dopamina.
BRPI0911772A2 (pt)	2008-04-29	2017-06-27	Nsab Filial Af Neurosearch Sweden Ab Sverige	composto, composição farmacêutica, e, uso do composto.
EP2271635A1 (en) *	2008-04-29	2011-01-12	NSAB, Filial af NeuroSearch Sweden AB, Sverige	Modulators of dopamine neurotransmission
TW201024282A (en) *	2008-11-20	2010-07-01	Orion Corp	New pharmaceutical compounds
US8822679B2 (en) *	2011-06-24	2014-09-02	California Institute Of Technology	Quaternary heteroatom containing compounds
US20130267699A1 (en)	2011-06-24	2013-10-10	California Institute Of Technology	Quaternary heteroatom containing compounds
US9518034B2 (en)	2013-10-14	2016-12-13	California Institute Of Technology	Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
US10421696B2 (en)	2014-12-18	2019-09-24	California Institute Of Technology	Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN108774274B (zh) *	2015-03-06	2020-11-03	北京大学	唾液酸甲酯甲苷衍生物及其合成方法和应用
CA2981041C (en)	2015-03-27	2023-09-05	California Institute Of Technology	Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
AR104882A1 (es)	2015-06-05	2017-08-23	Orion Corp	DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C
WO2017156239A1 (en)	2016-03-11	2017-09-14	California Institute Of Technology	Compositions and methods for acylating lactams
KR20190020343A (ko) *	2016-06-29	2019-02-28	오리온 코포레이션	벤조디옥산 유도체 및 이의 약제학적 용도
CN110662541B (zh) *	2017-03-12	2023-02-10	王晓冬	多环胺作为阿片受体调节剂
US10358422B2 (en)	2017-11-01	2019-07-23	California Institute Of Technology	Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
GB201801130D0 (en) *	2018-01-24	2018-03-07	Univ Oxford Innovation Ltd	Compounds
SG11202101821TA (en) *	2018-09-25	2021-03-30	Bayer Ag	a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
US11214568B2 (en)	2018-10-18	2022-01-04	California Institute Of Technology	Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
AU2023205425A1 (en)	2022-01-07	2024-07-25	Bayer Aktiengesellschaft	α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
KR102776660B1 (ko) *	2022-01-25	2025-03-04	재단법인 한국파스퇴르연구소	벤조다이옥세인 유도체 화합물 및 이의 의약 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2056046A (en)	1933-05-19	1936-09-29	Rhone Poulenc Sa	Manufacture of bases derived from benz-dioxane
US3635982A (en)	1969-04-08	1972-01-18	American Home Prod	Amino-substituted-quinoxalinyloxazolidines and -oxazines
GB1411531A (en)	1972-10-24	1975-10-29	Lafon Labor	Amino derivatives of 1,4-benzodioxan
JPS5163193A (ja) *	1974-11-26	1976-06-01	Yoshitomi Pharmaceutical	Tetorahidoropirazoropirijinkagobutsuno seizoho
US4039676A (en)	1975-06-23	1977-08-02	Ciba-Geigy Corporation	2-piperidinoalkyl-1,4-benzodioxans
US4329348A (en)	1979-02-26	1982-05-11	Ciba-Geigy Corporation	N-Oxacyclic-alkylpiperidines as psychostimulants
HU181575B (en)	1980-10-03	1983-10-28	Richter Gedeon Vegyeszet	Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives
FR2525600A1 (fr) *	1982-04-21	1983-10-28	Bouchara Emile	Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
GB2167408B (en)	1984-11-23	1988-05-25	Farmos Oy	Substituted imidazole derivatives and their preparation and use
DD250930A1 (de)	1986-06-08	1987-10-28	Isis Chemie Zwickau Veb	Verfahren zur herstellung neuer tetrahydroisochinolinderivate
US4957928A (en) *	1986-06-26	1990-09-18	Ciba-Geigy Corporation	Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
JPH04500075A (ja)	1988-08-16	1992-01-09	イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー	殺菌性ベンゾジオキサンアミン誘導体
CA2104873C (en)	1991-02-26	2000-05-23	James N. Campbell	Compositions and methods of treatment of sympathetically maintained pain
GB9318431D0 (en) *	1993-09-06	1993-10-20	Boots Co Plc	Therapeutic agents
GB9514380D0 (en)	1995-07-13	1995-09-13	Knoll Ag	Therapeutic agents
FR2744451B1 (fr) *	1996-02-01	1998-04-24	Pf Medicament	Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
EP0983239A1 (en)	1997-05-06	2000-03-08	Novo Nordisk A/S	Novel heterocyclic compounds
US5902807A (en)	1997-05-12	1999-05-11	Antti Haapalinna	Method for the treatment of mental illness in mammals and a composition therefor
SK8542000A3 (en)	1997-12-04	2001-03-12	Allergan Sales Inc	Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
FI20000480A0 (fi)	2000-03-01	2000-03-01	Orion Yhtymae Oyj	Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
AU2001290873B2 (en) *	2000-09-11	2006-07-27	Sepracor Inc.	Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
US7592350B2 (en)	2002-04-03	2009-09-22	Orion Corporation	Polycyclic compounds as potent alpha2-adrenoceptor antagonists
WO2004067513A1 (en)	2003-01-27	2004-08-12	Oy Juvantia Pharma Ltd	Antagonists for alpha-2 adrenoceptors
TWI457122B (zh)	2007-07-20	2014-10-21	Orion Corp	作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP5163193B2 (ja)	2008-03-13	2013-03-13	セイコーエプソン株式会社	プリンタシステム及びプリンタシステムにおける制御方法

2008
- 2008-07-02 TW TW097124840A patent/TWI457122B/zh active
- 2008-07-17 AR ARP080103087A patent/AR069271A1/es active IP Right Grant
- 2008-07-17 CL CL2008002114A patent/CL2008002114A1/es unknown
- 2008-07-17 PE PE2008001216A patent/PE20090890A1/es active IP Right Grant
- 2008-07-18 WO PCT/FI2008/000090 patent/WO2009013390A1/en active Application Filing
- 2008-07-18 UA UAA201001749A patent/UA100695C2/ru unknown
- 2008-07-18 KR KR1020107003606A patent/KR101535059B1/ko active Active
- 2008-07-18 AU AU2008278924A patent/AU2008278924B2/en active Active
- 2008-07-18 PL PL08787689T patent/PL2176252T3/pl unknown
- 2008-07-18 EA EA201070169A patent/EA017554B1/ru not_active IP Right Cessation
- 2008-07-18 DK DK08787689.2T patent/DK2176252T3/en active
- 2008-07-18 JP JP2010516529A patent/JP5460590B2/ja active Active
- 2008-07-18 NZ NZ582432A patent/NZ582432A/en unknown
- 2008-07-18 PT PT87876892T patent/PT2176252E/pt unknown
- 2008-07-18 GE GEAP200811693A patent/GEP20125538B/en unknown
- 2008-07-18 BR BRPI0814529A patent/BRPI0814529B8/pt active IP Right Grant
- 2008-07-18 CA CA2693804A patent/CA2693804C/en active Active
- 2008-07-18 ES ES08787689.2T patent/ES2502215T3/es active Active
- 2008-07-18 SI SI200831313T patent/SI2176252T1/sl unknown
- 2008-07-18 RS RSP20140510 patent/RS53571B1/en unknown
- 2008-07-18 US US12/668,918 patent/US8492549B2/en active Active
- 2008-07-18 CN CN200880025445.8A patent/CN101842369B/zh active Active
- 2008-07-18 EP EP08787689.2A patent/EP2176252B1/en active Active
- 2008-07-18 MY MYPI2010000086A patent/MY153872A/en unknown
2009
- 2009-12-24 IL IL202964A patent/IL202964A/en active IP Right Grant
2010
- 2010-01-15 TN TNP2010000029A patent/TN2010000029A1/fr unknown
- 2010-01-15 MA MA32515A patent/MA31521B1/fr unknown
- 2010-01-15 ZA ZA201000314A patent/ZA201000314B/xx unknown
- 2010-01-19 CO CO10004690A patent/CO6331473A2/es active IP Right Grant
2011
- 2011-03-21 HK HK11102788.9A patent/HK1148530A1/xx unknown
2013
- 2013-06-14 US US13/917,745 patent/US8697723B2/en active Active
2014
- 2014-02-27 US US14/192,131 patent/US8809536B2/en active Active
- 2014-11-26 CY CY20141100982T patent/CY1115789T1/el unknown
- 2014-11-27 HR HRP20141156AT patent/HRP20141156T1/hr unknown

Also Published As

Publication number	Publication date
CN101842369B (zh)	2014-01-22
HRP20141156T1 (hr)	2015-01-16
NZ582432A (en)	2012-03-30
PT2176252E (pt)	2014-12-03
AU2008278924B2 (en)	2013-09-26
WO2009013390A1 (en)	2009-01-29
CY1115789T1 (el)	2017-01-25
TWI457122B (zh)	2014-10-21
KR20100044220A (ko)	2010-04-29
AU2008278924A1 (en)	2009-01-29
CA2693804A1 (en)	2009-01-29
HK1148530A1 (en)	2011-09-09
CN101842369A (zh)	2010-09-22
US8492549B2 (en)	2013-07-23
AR069271A1 (es)	2010-01-13
ES2502215T3 (es)	2014-10-03
TW200908961A (en)	2009-03-01
PE20090890A1 (es)	2009-07-08
DK2176252T3 (en)	2014-12-08
TN2010000029A1 (en)	2011-09-26
MY153872A (en)	2015-03-31
EA017554B1 (ru)	2013-01-30
CO6331473A2 (es)	2011-10-20
PL2176252T3 (pl)	2015-04-30
EP2176252A1 (en)	2010-04-21
JP2010534197A (ja)	2010-11-04
MA31521B1 (fr)	2010-07-01
RS53571B1 (en)	2015-02-27
IL202964A (en)	2013-12-31
US20140179926A1 (en)	2014-06-26
EP2176252B1 (en)	2014-09-03
BRPI0814529B8 (pt)	2021-05-25
GEP20125538B (en)	2012-05-25
EA201070169A1 (ru)	2010-06-30
US20100216836A1 (en)	2010-08-26
US20130281486A1 (en)	2013-10-24
ZA201000314B (en)	2010-10-27
UA100695C2 (ru)	2013-01-25
BRPI0814529B1 (pt)	2019-09-17
US8697723B2 (en)	2014-04-15
KR101535059B1 (ko)	2015-07-24
CL2008002114A1 (es)	2009-04-03
US20120035210A9 (en)	2012-02-09
BRPI0814529A2 (pt)	2015-01-27
JP5460590B2 (ja)	2014-04-02
CA2693804C (en)	2015-11-24
US8809536B2 (en)	2014-08-19

Publication	Publication Date	Title
SI2176252T1 (sl)	2014-12-31	2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
HK1166983A1 (zh)	2012-11-16	包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
HUE059861T2 (hu)	2023-01-28	N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL216967B (en)	2018-06-28	The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
EP2166837A4 (en)	2011-12-21	DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
ZA201000075B (en)	2010-09-29	Purin derivatives for use in the treatment of fab-related diseases
IL195906A0 (en)	2009-09-01	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL202424A (en)	2017-01-31	Telomerase activator compounds for use in the treatment of disorders and related conditions
IL213168A0 (en)	2011-07-31	1,2,4-oxadiazole derivatives and their therapeutic use
IL205608A (en)	2016-03-31	History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication
PL2401263T3 (pl)	2016-08-31	Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
EP2148667A4 (en)	2010-06-02	USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
IL206173A0 (en)	2010-12-30	5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
PL2238119T3 (pl)	2016-05-31	Chinazoliny i pokrewne związki heterocykliczne i ich zastosowanie terapeutyczne
GB0909297D0 (en)	2009-07-15	Composition for the treatment of skin conditions
EP2207555A4 (en)	2010-11-24	NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF
IL217300A0 (en)	2012-02-29	Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
ZA201108106B (en)	2013-07-31	Use of phthalimide derivatives in the treatment of diseases
IL192933A0 (en)	2009-02-11	Benzoisoindole derivatives for the treatment of pain
GB0620695D0 (en)	2006-11-29	Composition and methods for the treatment of nurdegenerative disease
GB0710277D0 (en)	2007-07-11	Use of antivirals in the treatment of medical disorders
IL202474A0 (en)	2010-06-30	1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof
ZA201000582B (en)	2011-04-28	1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives,preparation and therapeutic use thereof
IL200732A0 (en)	2010-05-17	Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases
EP2285365A4 (en)	2011-02-23	USE OF A COMPOSITION COMPRISING AT LEAST ONE BETABILITY TREATMENT FOR THE TREATMENT OF SLEEP DISORDERS